Choroidal neovascularization

This study tests a new medicine called tiespectus (EYE201) for wet age-related macular degeneration, a leading cause of vision loss. About 960 people will receive either tiespectus or the standard treatment aflibercept via eye injections. The goal is to see if tiespectus can impr…

This study tests a new drug called tiespectus (MK-8748) against the current standard treatment, aflibercept, for people with wet age-related macular degeneration (AMD). About 960 participants will receive injections into the eye and be followed for a year to see if tiespectus can…

This study tests whether faricimab (Vabysmo) injections given every 12-16 weeks can maintain stability in people with wet age-related macular degeneration (AMD) after an initial series of loading doses. The trial will enroll 40 adults over 50 with active wet AMD. The main goal is…

This study is testing a home-based eye-tracking system called AVIGA to see if it can detect when wet age-related macular degeneration (AMD) comes back. Sixty adults aged 50-99 who are being treated for wet AMD will use the AVIGA device at home, and its accuracy will be compared t…

This study tests a new 3D ultrasound probe to see tiny blood vessels inside fatty plaques in the neck arteries. These vessels can make plaques more likely to rupture and cause a stroke. Ten people who already had a standard ultrasound will get this new 3D scan with a contrast dye…

This study analyzes blood and aqueous humor (eye fluid) from 250 people with type 1 choroidal neovascularization—a cause of vision loss—and from controls without the condition. Researchers measure biomarker levels and check whether they correlate with how well patients respond to…